<DOC>
	<DOCNO>NCT00356512</DOCNO>
	<brief_summary>This study explore regulation fibroblast growth factor-23 ( FGF-23 ) . It hormone recently identify regulator blood level phosphorus vitamin D , essential overall health especially important bone health . The parathyroid hormone ( PTH ) regulate phosphorus calcium , people hypoparathyroidism pseudohypoparathyroidism sufficient PTH action . There genetic disease influence FGF-23 , cause abnormal metabolism phosphorus vitamin D , thus affect bone . Also , rare tumor may cause overproduction FGF-23 causing debilitate bone disease . Patients age 18 old low PTH level , resistant PTH action , take calcitriol calcium supplement , pregnant , kidney disorder may eligible study . During 4-day study , patient provide control diet low usual phosphorus content . On day 1 , patient admit NIH Clinic Center undergo blood urine test measure calcium , phosphorus , vitamin D , FGF-23 . They continue regular medicine hypoparathyroidism . On day throughout study , patient fast 10:00 p.m. 8:00 a.m. follow day . On day 2 , patient continue fast 4:00 p.m. A tube place vein arm : one draw blood infuse calcium . Just one intravenous ( IV ) line use day . Patients receive calcium chloride 8 hour , dose carefully monitored machine . The purpose bring blood calcium level high normal range . Blood urine sample collect periodically , check effect calcium chloride FGF-23 PTH . On day 3 4 , patient take calcitriol calcium receive injection PTH , skin , two time day . On day 3 , blood urine sample collect analysis . On day 4 , patient receive one dose calcitriol IV . The total amount blood drawn study 5 ounce .</brief_summary>
	<brief_title>Physiologic Regulation FGF-23</brief_title>
	<detailed_description>Vitamin D phosphate central normal mineral homeostasis important many physiologic function include skeletal integrity . For several decade parathyroid hormone ( PTH ) recognize central regulator serum vitamin D phosphate level . Recently , FGF-23 identify central regulation metabolism vitamin D serum phosphorus . The organ primarily responsible physiologic production FGF-23 appear skeleton . The study FGF-23 metabolism direct effect mineral metabolism confound classic endocrine feedback loop exist among serum calcium , phosphorus , 1,25- ( OH ) 2-vitamin D ( 1,25-D ) , PTH . It possible ( phosphorus , calcium , 1,25-D , and/or PTH ) important regulation serum FGF-23 . The goal study identify factor regulate serum FGF-23 . To overcome confound effect PTH , study patient deficient PTH ( hypoparathyroidism ) resistant PTH kidney ( pseudohypoparathyroidism type 1B , PHP1B ) . The kidney one primary organ responsible regulate serum phosphorus generate 1,25-D . It target PTH FGF-23 . While patient PHP1B resistant action PTH kidney , sensitive action PTH bone , tissue produce FGF-23 . Physiologic manipulation serum phosphorus , 1,25-D , calcium , PTH subject hypoparathyroidism PHP1B allow nearly complete dissection factor potential regulator serum FGF-23 .</detailed_description>
	<mesh_term>Hypoparathyroidism</mesh_term>
	<criteria>INCLUSION CRITERIA Adult hypoparathyroid patient , define low inappropriately normal PTH level despite hypocalcemia , stable treatment regimen calcitriol calcium supplementation , willing participate study eligible . Adult PHP1B patient define clinical syndrome elevate PTH phosphorus confirm methylation analysis GNAS gene . EXCLUSION CRITERIA Renal insufficiency evidence creatinine clearance le 50 ml/min Medically unstable patient Uncontrolled comorbid condition , e.g. , diabetes , coronary artery disease , congestive heart failure , cerebrovascular disease . Digitalis therapy Patients diuretic therapy , especially thiazides Pregnant lactate woman Patients whose hypoparathyroidism cause severe calciumsensing receptor defect . These patient begin mark symptom `` hypercalcemia '' serum calcium midnormal range . Patients 18 year age Patients history bone cancer , skeletal metastasis previous radiotherapy skeleton , unexplained elevation serum alkaline phosphatase</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2, 2009</verification_date>
	<keyword>Phosphate</keyword>
	<keyword>Vitamin D</keyword>
	<keyword>Hypoparathyroidism</keyword>
	<keyword>Phosphatonin</keyword>
	<keyword>Clamp</keyword>
</DOC>